FindMyKOL
Clinical trialNCT01173159CompletedInterventional

Compassionate Use of Omegaven to Reverse Parenteral Nutrition Induced Cholestasis

NCT01173159 is an interventional trial sponsored by Children's Hospital Medical Center, Cincinnati. As of 21 Nov 2026, it is completed. It studies Omegaven in Cholestasis. The registry lists an enrollment of 10 participants at 1 site in 1 country. The registry lists a start date of 31 Jul 2010 and a primary completion date of 31 Dec 2018.

SponsorChildren's Hospital Medical Center, CincinnatiEnrollment10Cholestasis
View the registry record on ClinicalTrials.gov

Key facts

Registry attributes as recorded on the ClinicalTrials.gov study record.

Key facts for NCT01173159
FieldValue
Registry IDNCT01173159
StatusCompleted
Study typeInterventional trial
Lead sponsorChildren's Hospital Medical Center, Cincinnati
Enrollment10
Registered sites1
Countries1
ConditionsCholestasis
DrugsOmegaven
Start31 Jul 2010
Primary completion31 Dec 2018
Study completion31 Dec 2018
Last update posted17 Jun 2020

Registered summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The purpose of this research study is to see if giving Omegaven (an intravenous fat emulsion containing fish oil) instead of the current lipid emulsion, which contains fat derived from soybeans, as part of your child's intravenous (IV) nutrition therapy may be tolerated better. It may reduce the harmful effects to the liver, may stop any further liver damage and may reverse damage already done to the liver because of the prolonged use of nutrition through your child's IV.

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Ohio, United States1 site
  • Cincinnati Children's Hospital Medical Center

    Cincinnati

United States, by state

AlaskaAKMaineMEVermontVTNew HampshireNHWashingtonWAMontanaMTNorth DakotaNDMinnesotaMNWisconsinWIMichiganMINew YorkNYMassachusettsMARhode IslandRIOregonORIdahoIDSouth DakotaSDIowaIAIllinoisILIndianaINOhio: 1 siteOH1PennsylvaniaPANew JerseyNJConnecticutCTCaliforniaCANevadaNVWyomingWYNebraskaNEMissouriMOKentuckyKYWest VirginiaWVVirginiaVAMarylandMDDelawareDEArizonaAZUtahUTColoradoCOKansasKSArkansasARTennesseeTNNorth CarolinaNCSouth CarolinaSCNew MexicoNMOklahomaOKLouisianaLAMississippiMSAlabamaALGeorgiaGAHawaiiHITexasTXFloridaFLDistrict of ColumbiaDC
Fewer sitesMore sites

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Omegaven
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Questions about NCT01173159

Each answer restates registry values shown on this page.

What is NCT01173159?

NCT01173159 is an interventional trial sponsored by Children's Hospital Medical Center, Cincinnati. It studies Omegaven in Cholestasis.

Who leads NCT01173159?

The registry names Samuel Kocoshis, MD (principal investigator, Children's Hospital Medical Center, Cincinnati) as the overall official.

Where does NCT01173159 run?

The registry lists 1 site in 1 country. Every site with a stated country is in one country: United States.

Which drugs does NCT01173159 study?

The registered drug and biological interventions are Omegaven.

When did NCT01173159 end?

The registry lists a primary completion date of 31 Dec 2018 and a study completion date of 31 Dec 2018. The sponsor last updated the record on 17 Jun 2020.

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.